HLS Therapeutics Inc.
HLTRF
$3.36
-$0.07-1.98%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -1.98% | -1.92% | -4.20% | -6.61% | -10.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.98% | -1.92% | -4.20% | -6.61% | -10.23% |
| Cost of Revenue | 7.71% | 9.63% | 9.68% | 12.67% | 11.08% |
| Gross Profit | -5.36% | -5.81% | -8.62% | -12.23% | -15.87% |
| SG&A Expenses | -18.31% | -14.14% | -11.36% | -9.23% | -4.80% |
| Depreciation & Amortization | -3.96% | -10.45% | -19.40% | -24.99% | -28.87% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.31% | -7.55% | -10.16% | -11.54% | -12.42% |
| Operating Income | 46.58% | 45.33% | 46.56% | 39.72% | 25.73% |
| Income Before Tax | 17.37% | 23.03% | 27.43% | 50.52% | 43.96% |
| Income Tax Expenses | -110.93% | -92.94% | -93.37% | 1,662.84% | 1,597.43% |
| Earnings from Continuing Operations | 36.76% | 35.92% | 37.55% | 35.41% | 28.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.76% | 35.92% | 37.55% | 35.41% | 28.61% |
| EBIT | 46.58% | 45.33% | 46.56% | 39.72% | 25.73% |
| EBITDA | 18.12% | 5.69% | -6.69% | -18.94% | -32.38% |
| EPS Basic | 37.22% | 34.91% | 36.56% | 34.14% | 27.15% |
| Normalized Basic EPS | 32.01% | 32.25% | 29.05% | 18.81% | 11.21% |
| EPS Diluted | 37.20% | 33.83% | 35.57% | 33.50% | 26.66% |
| Normalized Diluted EPS | 32.01% | 32.25% | 29.05% | 18.81% | 11.21% |
| Average Basic Shares Outstanding | 2.01% | -1.69% | -1.74% | -2.16% | -2.37% |
| Average Diluted Shares Outstanding | 2.01% | -1.69% | -1.74% | -2.16% | -2.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |